Blog Coverage VWR Corporation Announces Two Acquisitions

Upcoming AWS Coverage on Thermo Fisher Scientific Post-Earnings Results

LONDON, UK / ACCESSWIRE / November 4, 2016 / Active Wall St. blog coverage looks at the headline from the leading global independent provider of product and service solutions to laboratory and production customers, VWR Corp. (NASDAQ: VWR) (“VWR”) as the company announced on November 3rd, 2016, the acquisition of two companies, Reliable Biopharmaceutical and BioArra. The company did not disclose the financial details of the transactions. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.

On October 27, 2016, one of VWR Corp.’s competitors within the Medical Laboratories & Research space, Thermo Fisher Scientific, Inc. (NYSE: TMO), reported its financial results for Q3 2016, ended October 1, 2016. AWS will be initiating a research report on Thermo Fisher Scientific in the coming days.

Today, AWS is promoting its blog coverage on VWR; touching on TMO. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/registration-3/?symbol=VWR

http://www.activewallst.com/registration-3/?symbol=TMO

Reliable Biopharmaceutical is a manufacturer of high quality active pharmaceutical ingredients (APIs) and high purity ingredients (HPIs) such as cGMP excipients and advanced intermediates for the biopharmaceutical industry. Based in St. Louis, Missouri and founded in 1968, Reliable Biopharmaceutical is a key supplier for many pharmaceutical, biopharmaceutical, diagnostic and cosmetic companies. Reliable Biopharmaceutical offers highly-flexible, scalable and solution oriented production ranging from small batch clinical manufacturing to full scale commercial production.

Benefit for VWR: The company believes that the Reliable Biopharma’s acquisition will enhance its growing custom chemical and biochemical manufacturing portfolio.
BioArra is a leading producer of U.S. origin serum-based products for use in research and production. Founded in 2008 and headquartered in Eagleville, Pennsylvania, BioArra produces semi-processed serum from various USDA approved supplier locations.

Benefit for VWR: The company believes that the BioArra’s acquisition will strengthen its support to cellular science customers.

“BioArra and Reliable Biopharmaceutical greatly complement our previous acquisitions,” said Manuel Brocke-Benz, President and CEO of VWR, “Aligned with our overall mergers and acquisitions strategy, these acquisitions continue to broaden our capabilities to provide value-added services and high quality products to our customers.”

Acquisition Strategy

Commenting on its third acquisition for the year, VWR stated that along with Therapak, PAW and JM Separations, these transactions will help the company to strengthen its business mode. VWR noted that it typically spends about $75 million on acquisitions on an annual basis. However, the company is expecting elevated spending of approximately $145 million this year as a result of attractive acquisition opportunities that became available. The company noted that since 2007, its average acquisition size has been approximately $16 million. VWR noted that it would consider slightly larger deal or alternatives for capital deployment. VWR added that these are very small acquisitions into a niche space in single use technology. The company believes that as platform acquisitions, they will take a while to develop from a commercial perspective, through the VWR channels; the company expects the combined revenue from the acquisition to be less than $10 million this year.

VWR Earnings Results

On November 03rd, 2016, VWR in its Q3 2016 financial results reported net sales of $1.14 billion, 3.7% compared to the prior year. Acquisitions added 2.8% to Q3 2016 revenues. The company’s operating income in the reported quarter was $83.2 million, up 2.6% on y-o-y basis. Q3 2016 diluted EPS was $0.31 as compared to $0.08 in Q3 2015. At September 30, 2016, VWR’s total debt was $2.02 billion and cash was $141.7 million. For the first nine months of 2016, cash provided by operating activities was $186.1 million compared to $157.3 million in the first nine months of 2015.

Stock Performance

At the close of trading session on Thursday, November 03, 2016, VWR Corp.’s stock price dropped 4.56% to end the day at $26.15. A total volume of 2.26 million shares were exchanged during the session, which was above the 3-month average volume of 713.34 thousand shares. The stock currently has a market cap of $3.44 billion and trades at a PE ratio of 23.71.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 448329